Exagen Inc., a leader in autoimmune diagnostic testing, announced its participation in two upcoming investor conferences in November 2026: Canaccord Genuity’s MedTech Forum on November 11 and Craig-Hallum's Alpha Select Conference on November 17. These events provide Exagen a platform to showcase its innovative autoimmune testing solutions, including its flagship AVISE® CTD test, which aids in diagnosing complex autoimmune diseases. The company continues to advance care through research and innovation, aiming to support physicians with precise diagnostic tools. Investors can anticipate further updates, including Exagen's third quarter financial results scheduled for November 10, 2026.
Exagen Inc.'s upcoming participation in investor conferences is noted here alongside current health sector market data from Pluang. For readers following health stocks, as of Oct 29, 2026 19:12 WIB, 91 of 150 priced US health-sector stocks rose while 53 fell. Notable movers include Eli Lilly And Co (LLY) at USD 1,350.62 with a 4.80% increase and Pluang order activity showing 29% Sell / 71% Buy, Incyte Corporation (INCY) at USD 112.32 down 3.89% with 0% Sell / 100% Buy, and Amgen, Inc. (AMGN) at USD 468.69 up 3.73% with 18% Sell / 82% Buy.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
